Therapeutics News and Research

RSS

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).

9 Aug 2012

Global market value of Alzheimer's disease therapeutics could soar to $8 billion: GEN

The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN).

8 Aug 2012

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Chemotherapy kills tumor cells, but it also wreaks havoc on the rest of the body. A team of researchers led by Igor Roninson of the South Carolina College of Pharmacy just reported the discovery of a new class of drugs that reduces the adverse effects of cellular damage from chemotherapy.

8 Aug 2012

Back pain sufferers show quick response to chiropractic therapy

Patients with low back pain undergoing chiropractic treatment who respond to treatment are likely to improve very quickly, study findings show.

7 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2012.

7 Aug 2012

Scripps Florida scientists to identify and develop new therapeutic approaches against cancers

Scientists from the Florida campus of The Scripps Research Institute have been awarded approximately $1.5 million from the National Institutes of Health to identify and develop new therapeutic approaches against a broad spectrum of cancers.

7 Aug 2012

New Translational Oncology Program at University of Michigan

The University of Michigan Comprehensive Cancer Center is harnessing its expertise in basic science research to speed the translation into clinical trials and new treatment opportunities for cancer patients.

6 Aug 2012

CPRIT awards $48.2 million in new grants to investigators at UT Southwestern Medical Center

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $48.2 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer researchers.

6 Aug 2012

Potential drug targets and prognostic markers for prostate cancer

Two proteins that act in opposing directions - one that promotes cancer and one that suppresses cancer - regulate the same set of genes in prostate cancer, Vanderbilt-Ingram Cancer Center researchers have found.

6 Aug 2012

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

Clovis Oncology, Foundation Medicine enter diagnostic collaboration

Foundation Medicine, Inc. and Clovis Oncology, Inc. announced today that they have entered into a diagnostic collaboration.

6 Aug 2012

Drug molecules designed for influenza may be adapted to treat other viruses

St. Jude Children's Research Hospital study shows how compounds blocking an enzyme universal to all influenza viruses may allow development of new antiviral drugs that also avoid the problem of drug resistance

3 Aug 2012

Exposure to mold during infancy linked to asthma development during childhood

In the United States, one in 10 children suffers from asthma but the potential environmental factors contributing to the disease are not well known. Cincinnati-based researchers now report new evidence that exposure to three types of mold during infancy may have a direct link to asthma development during childhood.

3 Aug 2012

HSF1 increases expression of chaperones and supports cancer metastasis

Whitehead Institute researchers have found that increased expression of a specific set of genes is strongly associated with metastasis and death in patients with breast, colon, and lung cancers.

3 Aug 2012

New method could increase number of genetic components in synthetic biologists' toolkit

Through the assembly of genetic components into "circuits" that perform logical operations in living cells, synthetic biologists aim to artificially empower cells to solve critical problems in medicine, energy and the environment. To succeed, however, they'll need far more reliable genetic components than the small number of "off-the-shelf" bacterial parts now available.

3 Aug 2012

Therapeutics News and Research

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Global market value of Alzheimer's disease therapeutics could soar to $8 billion: GEN

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Back pain sufferers show quick response to chiropractic therapy

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Scripps Florida scientists to identify and develop new therapeutic approaches against cancers

New Translational Oncology Program at University of Michigan

CPRIT awards $48.2 million in new grants to investigators at UT Southwestern Medical Center

Potential drug targets and prognostic markers for prostate cancer

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Clovis Oncology, Foundation Medicine enter diagnostic collaboration

Drug molecules designed for influenza may be adapted to treat other viruses

Exposure to mold during infancy linked to asthma development during childhood

HSF1 increases expression of chaperones and supports cancer metastasis

New method could increase number of genetic components in synthetic biologists' toolkit

Glutamatergic system involvement in BD supported

Researchers discover genetic process that can restore function to a CF defective protein

Researchers discover new approach to treat two lethal metastatic cancers

Hyperion Therapeutics announces completion of initial public offering

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News